Nanoviricides Stock Price, News & Analysis

NanoViricides (NYSE:NNVC) reported Q3 2024 financial results with cash and equivalents of $3.87 Million and net property assets of $7.36 Million. The company's lead drug candidate NV-387, a broad-spectrum antiviral, is progressing toward Phase II clinical trials for multiple indications including MPOX, RSV, Influenza, and COVID. A Phase Ia/Ib trial was completed with no adverse events. The company raised $1.71 million through ATM offering and has access to a $3 million credit line, though additional funding will be needed for planned Phase II trials. NV-387 has shown promising results in animal trials, potentially offering superior effectiveness compared to existing treatments for various viral infections.

NanoViricides (NYSE:NNVC) announces a corporate presentation at the Spartan Capital Investors Conference 2024 on November 4, featuring their lead drug candidate NV-387. The presentation will highlight NV-387's completion of Phase I clinical trials and its demonstrated antiviral activity against multiple viruses including Influenza, RSV, COVID, and MPox/Smallpox. The company notes that NV-387 targets a market estimated at $2.5 to $4.3 billion for RSV alone, with the overall market for targeted indications projected to exceed $10 billion by 2027.

NanoViricides announces that Dr. Anil R. Diwan, President and Executive Chairman, will present at the PODD Conference on October 28, 2024, at 3:45 PM. The conference will take place at the Westin Boston Seaport District, MA. Dr. Diwan's talk, titled 'Revolutionizing Antiviral Treatments, Phase 2-Ready, Orally Available Nanomedicines That Can Deliver Difficult APIs And Improve PK', will focus on the nanoviricides platform technology and its achievements.

Key points include the broad-spectrum drug candidate NV-387, which has completed Phase 1 trials with excellent safety and efficacy against various viruses, including RSV, Influenza A/H3N2, coronavirus, and poxvirus. NV-387 is orally available and has shown superior results compared to existing treatments like oseltamivir, peramivir, and remdesivir in animal models. Dr. Diwan will also discuss the platform's potential to revolutionize drug delivery, enabling oral availability and protection from metabolism for difficult drugs.

NanoViricides, Inc. (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, was interviewed in a PODD Conference podcast. Dr. Diwan discussed the company's nanoviricides technology platform and its broad-spectrum antiviral clinical drug candidate NV-387. He explained how NV-387 could revolutionize viral infection treatment, similar to penicillin's impact on bacterial infections.

Dr. Diwan highlighted NV-387's potential to resist viral escape and the company's multiple Phase II clinical trial strategies. He also elaborated on how the nanoviricide platform can aid other pharmaceutical innovators in developing effective drugs. The technology enables oral drug delivery of difficult-to-dose APIs, protects APIs from bodily metabolism, and allows for targeted drug delivery to specific cells or pathogens.

NanoViricides (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, will present at the Global AMR Summit 2024 on October 9, 2024, in Cambridge, MA. Dr. Diwan will discuss the company's 'Trojan Horse' Platform Technology to combat antimicrobial resistance (AMR).

The technology enables delivery of 'war-heads' directly onto pathogens, potentially reducing toxicity and improving pharmacokinetics. NanoViricides' lead drug, NV-387, has completed Phase 1a/1b trials with no reported adverse events. It has shown strong antiviral activity against multiple virus families, including Coronaviruses, RSV, and Influenza A.

NV-387 could be the first single drug to treat all 'tripledemic' viral infections. The company is also developing 'dual-action' nanoviricides to potentially cure viral infections by blocking the complete Virus Life Cycle.

NanoViricides has filed its Annual Report for the fiscal year ending June 30, 2024. As of June 30, 2024, the company reported approximately $4.97 million in cash and equivalents, $7.5 million in net property and equipment, and $1.36 million in total current liabilities. The company utilized $6.31 million for operating activities, including Phase Ia/Ib clinical trials of NV-387. NanoViricides raised $3.12 million through an At-the-Market offering and an additional $1.53 million subsequently, increasing its available cash to approximately $9.5 million. Despite this, the company expressed substantial doubt about its ability to continue operations through September 2025 without additional funding. NV-387, a broad-spectrum antiviral, has shown promise in preclinical trials and is advancing to Phase II clinical trials for RSV and MPOX. The company is exploring non-dilutive funding and partnerships to support its objectives.

NanoViricides has signed a Memorandum of Understanding (MoU) with TheraCour Pharma, granting it a right of first refusal (ROFR) for all antiviral drug developments. This agreement, made on September 23, 2024, includes intellectual property rights for developing treatments against any viral infections.

The company's lead drug, NV-387, has shown promising results in animal studies against various viruses and is set to enter Phase II clinical trials for diseases like RSV, Influenza, Bird Flu, COVID, and MPOX/Smallpox. Additionally, the company has developed 'Trojan Horse' drugs that can target multiple stages of a virus's lifecycle.

This MoU allows NanoViricides to rapidly develop new antiviral drugs, even for unforeseen viruses, and negotiate licenses for specific antiviral fields. The nanoviricide technology aims to revolutionize antiviral treatments by mimicking host cells to destabilize viruses.

NanoViricides (NYSE:NNVC) is investigating the use of its drug candidate NV-387 to treat MPOX under the WHO MEURI protocol, following the recent MPOX outbreak declaration. Key points:

1. NV-387 completed Phase I trials with no adverse events reported.
2. It showed strong survival improvement in animal studies, matching the approved drug tecovirimat.
3. NV-387 was found superior or equivalent to existing drugs for RSV, Influenza, and COVID in non-clinical trials.
4. The current MPOX epidemic is caused by Clade 1/1b, which is more severe than the 2022 Clade 2 outbreak.
5. NV-387 acts via 'Re-Infection Inhibition', blocking virus cell infection.

The company believes NV-387 could be revolutionary for viral infection treatment if proven effective in human trials.

NanoViricides is progressing towards a Phase II clinical trial of its drug candidate NV-387, aimed at treating multiple viral infections including RSV, COVID, and Influenza. Dr. Anil Diwan is collaborating with experts to develop a trial plan and protocol. NV-387 has demonstrated strong effectiveness in animal studies and could potentially become a first-line treatment for respiratory viral infections, eliminating the need for testing virus types before treatment.

The estimated market size for these infections is over $8 billion in 2024, expected to grow to $12 billion by 2027. The Phase II trial will assess NV-387's effectiveness against multiple viruses in a single study, aiming to reduce costs and enhance return on investment. NV-387 recently completed a Phase I trial, showing good tolerability. The company envisions a new paradigm in treating viral infections, similar to broad-spectrum antibiotics for bacteria.